Life Sciences company focusing on developing and commercializing innovative solutions for treating mental health and addiction Mydecine Innovation Group. (NEO: MYCO) (OTC: MYCOF) has unveiled an artificial intelligence drug discovery program dubbed ‘in-silico’ which it’s conducting in partnership with researchers from University of Alberta.
This program will be focused on developing artificial intelligence/machine learning supported drug screening including both the ability to develop drugs from receptors up and evaluate drugs around the receptors selected by Mydecine.
This program will be led by leading computer aided drug development expert, Dr. Khaled Barakat.
“Dr. Barakat and his team have built an impressive reputation as leaders at the intersection of technology and pharmacological science. Adding their specialization in developing innovative computer models and novel technologies to predict protein-protein and protein-drug interactions will bring tremendous value to Mydecine’s research and enable us to more quickly bring to market effective drugs that can produce better outcomes for patients,” sait the company’s CEO, Josh Bartch.